News
EVO
3.220
+0.31%
0.010
Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Legend Biotech (LEGN) and Inogen (INGN)
TipRanks · 2d ago
Evotec assumed with a Buy at H.C. Wainwright
TipRanks · 2d ago
Evotec appoints Ingrid Muller as COO
TipRanks · 2d ago
Evotec names Ingrid Müller COO, effective May 1, 2026
PUBT · 2d ago
Berenberg Bank Keeps Their Buy Rating on Evotec (0IRF)
TipRanks · 3d ago
Weekly Report: what happened at EVO last week (0406-0410)?
Weekly Report · 4d ago
Deutsche Bank Keeps Their Hold Rating on Evotec (0IRF)
TipRanks · 4d ago
Goldman Sachs cuts Evotec voting rights to 8.1% from 8.2%
Reuters · 04/10 09:49
Sernova shareholders approved debt-for-equity unit issuance to Evotec SE at meeting
Reuters · 04/09 11:06
Limited Near-Term Visibility and Execution Risk Drive Sell Rating on Evotec Despite In-Line Results
TipRanks · 04/09 09:15
Evotec Earnings Call: Biologics Surge Amid Tough Reset
TipRanks · 04/09 00:03
Evotec (EVO) Q3 2025 Earnings Call Transcript
The Motley Fool · 04/08 19:38
Evotec Posts Strong 2025 Results and Accelerates Horizon Transformation With Major Biologics Deals
TipRanks · 04/08 16:12
Earnings Scheduled For April 8, 2026
Benzinga · 04/08 11:11
Evotec Sees FY2026 Sales $814.906M-$908.038M vs $957.470M Est
Benzinga · 04/08 10:30
Evotec Q4 EPS $0.05 Beats $0.02 Estimate, Sales $294.879M Beat $253.350M Estimate
Benzinga · 04/08 10:29
Evotec FY25 adjusted EBITDA climbs 82% to €41.1 million; revenue slips 1.1% to €788.4 million
Reuters · 04/08 05:31
Evotec Names New Supervisory Board Chair and Expects $100 Million Windfall From Tubulis Deal
TipRanks · 04/07 17:13
RBC Capital Remains a Buy on Evotec (0IRF)
TipRanks · 04/07 16:45
Evotec nominates Dieter Weinand as next supervisory board chair at AGM
Reuters · 04/07 16:21
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.